Cargando…

A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation

Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. These molecularly coordinated regions are named “variable chromatin modules” (VCMs), providing a conceptual framework of how regulatory variation might shape compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Llimos, Gerard, Gardeux, Vincent, Koch, Ute, Kribelbauer, Judith F., Hafner, Antonina, Alpern, Daniel, Pezoldt, Joern, Litovchenko, Maria, Russeil, Julie, Dainese, Riccardo, Moia, Riccardo, Mahmoud, Abdurraouf Mokhtar, Rossi, Davide, Gaidano, Gianluca, Plass, Christoph, Lutsik, Pavlo, Gerhauser, Clarissa, Waszak, Sebastian M., Boettiger, Alistair, Radtke, Freddy, Deplancke, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018852/
https://www.ncbi.nlm.nih.gov/pubmed/35440565
http://dx.doi.org/10.1038/s41467-022-29625-6
Descripción
Sumario:Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. These molecularly coordinated regions are named “variable chromatin modules” (VCMs), providing a conceptual framework of how regulatory variation might shape complex traits. To better understand the molecular mechanisms underlying VCM formation, here, we mechanistically dissect a VCM-modulating noncoding variant that is associated with reduced chronic lymphocytic leukemia (CLL) predisposition and disease progression. This common, germline variant constitutes a 5-bp indel that controls the activity of an AXIN2 gene-linked VCM by creating a MEF2 binding site, which, upon binding, activates a super-enhancer-like regulatory element. This triggers a large change in TF binding activity and chromatin state at an enhancer cluster spanning >150 kb, coinciding with subtle, long-range chromatin compaction and robust AXIN2 up-regulation. Our results support a model in which the indel acts as an AXIN2 VCM-activating TF nucleation event, which modulates CLL pathology.